In vitro kinetic assays for drug screening Studies on a variety of animal models Lead candidate selection and/or validation

Phase I/IIa

Target engagement Dose optimization and scheduling Single and multiple dosing

Phase II

Mild cognitive impairment/AD PK/PD correlations Responders versus non-responders

Phase III/IV

Adaptive drug trials Drug responders Clinical endpoint validation (PD correlations)